Literature DB >> 33165739

Molecular Mechanism of Platelet-Derived Growth Factor (PDGF)-BB-Mediated Protection Against MPP+ Toxicity in SH-SY5Y Cells.

Huan Chen1,2, Yan Teng1,2, Zhihao Liu2, Fan Geng2, Xingmin Chen2, Haisong Jiang1, Jing Yang2, Min Zheng2, Ziyan Wang3, Lu Yang4.   

Abstract

As an important endogenous growth factor, PDGF-BB can effectively promote neurogenesis, thus is considered as a potential agent for Parkinson's disease (PD) therapy. However, the protective function of PDGF-BB on neuronal cells, especially the molecular mechanism, remains less clear, which is needed to explore before its clinical practice. In this study, we investigated the function and mechanism of PDGF-BB against 1-methyl-4-phenylpyridinium (MPP+) toxicity in SH-SY5Y cells, a widely used cellular tool for PD-related molecular study. Our results indicated that PDGF-BB exerts a prominent protective effect against neurotoxin MPP+-triggered ROS generation and cellular loss. We further dissected the molecular mechanism involved in this process by using specific pharmacological inhibitors and validated that the distinct signaling pathways PI3K/Akt/GSK-3β and MEK/ERK are involved in the process against MPP+ toxicity upon PDGF-BB treatment. We also detected that activation of upstream PI3K/Akt/GSK-3β and MER/ERK signaling pathways contribute to phosphorylation and nuclear translocation of the downstream effector cyclic response element-binding protein (CREB), a known transcription factor to exhibit neuroprotective and growth-promoting effects. Using genetic approach, we further confirmed that the activation of CREB is involved in PDGF-BB-mediated protection in MPP+-exposed SH-SY5Y cells. Together, these data demonstrated the protective effect of PDGF-BB in MPP+-mediated toxicity in SH-SY5Y cells and verified the involved molecular mechanism in PDGF-BB-mediated neuroprotection.

Entities:  

Keywords:  Akt; CREB; ERK; MPP+; PDGF-BB; Parkinson’s disease

Year:  2020        PMID: 33165739     DOI: 10.1007/s12031-020-01735-0

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  30 in total

Review 1.  The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis?

Authors:  Hirokazu Fukui; Carlos T Moraes
Journal:  Trends Neurosci       Date:  2008-04-09       Impact factor: 13.837

Review 2.  Pharmacological treatment of Parkinson disease: a review.

Authors:  Barbara S Connolly; Anthony E Lang
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

Review 3.  Parkinson's disease.

Authors:  Lorraine V Kalia; Anthony E Lang
Journal:  Lancet       Date:  2015-04-19       Impact factor: 79.321

Review 4.  The epidemiology of Parkinson's disease: risk factors and prevention.

Authors:  Alberto Ascherio; Michael A Schwarzschild
Journal:  Lancet Neurol       Date:  2016-10-11       Impact factor: 44.182

5.  Metabolomic analysis revealed mitochondrial dysfunction and aberrant choline metabolism in MPP+-exposed SH-SY5Y cells.

Authors:  Taku Amo; Yutaka Oji; Shinji Saiki; Nobutaka Hattori
Journal:  Biochem Biophys Res Commun       Date:  2019-09-16       Impact factor: 3.575

6.  PDGF-BB protects mitochondria from rotenone in T98G cells.

Authors:  Ricardo Cabezas; Marcos Fidel Avila; Janneth González; Ramon Santos El-Bachá; George E Barreto
Journal:  Neurotox Res       Date:  2014-12-17       Impact factor: 3.911

7.  The neuroprotective effect of the GSK-3β inhibitor and influence on the extrinsic apoptosis in the ALS transgenic mice.

Authors:  Suk-Won Ahn; Jee-Eun Kim; Kyung Seok Park; Won-Jun Choi; Yoon-Ho Hong; Sung-Min Kim; Seung Hyun Kim; Kwang-Woo Lee; Jung-Joon Sung
Journal:  J Neurol Sci       Date:  2012-06-12       Impact factor: 3.181

Review 8.  Parkinson's disease: mechanisms and models.

Authors:  William Dauer; Serge Przedborski
Journal:  Neuron       Date:  2003-09-11       Impact factor: 17.173

9.  Regulation of morphine-induced synaptic alterations: Role of oxidative stress, ER stress, and autophagy.

Authors:  Yu Cai; Lu Yang; Guoku Hu; Xufeng Chen; Fang Niu; Li Yuan; Han Liu; Huangui Xiong; Jyothi Arikkath; Shilpa Buch
Journal:  J Cell Biol       Date:  2016-10-17       Impact factor: 10.539

Review 10.  Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates.

Authors:  Flore Gouel; Anne-Sophie Rolland; Jean-Christophe Devedjian; Thierry Burnouf; David Devos
Journal:  Front Neurol       Date:  2019-08-02       Impact factor: 4.003

View more
  3 in total

Review 1.  Insights Into the Role of Platelet-Derived Growth Factors: Implications for Parkinson's Disease Pathogenesis and Treatment.

Authors:  Dan Li; Le-Tian Huang; Cheng-Pu Zhang; Qiang Li; Jia-He Wang
Journal:  Front Aging Neurosci       Date:  2022-07-01       Impact factor: 5.702

Review 2.  Can the administration of platelet lysates to the brain help treat neurological disorders?

Authors:  Ouada Nebie; Luc Buée; David Blum; Thierry Burnouf
Journal:  Cell Mol Life Sci       Date:  2022-06-24       Impact factor: 9.207

3.  Platelet-derived growth factor (PDGF)-BB protects dopaminergic neurons via activation of Akt/ERK/CREB pathways to upregulate tyrosine hydroxylase.

Authors:  Huan Chen; Yan Teng; Xingmin Chen; Zhihao Liu; Fan Geng; Yanzhuo Liu; Haisong Jiang; Ziyan Wang; Lu Yang
Journal:  CNS Neurosci Ther       Date:  2021-08-04       Impact factor: 5.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.